Clinical Trial Update: A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Adult Patients With Moderate-to-Severe Atopic Dermatitis [Phase 2]

View source ↗

Summary

Phase 2b study evaluating rezpegaldesleukin (Rezpeg) for adults with moderate-to-severe atopic dermatitis is ongoing and currently not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• Rezpeg (rezpegaldesleukin)

Snippet

Sponsor: Nektar Therapeutics | Conditions: Moderate to Severe Atopic Dermatitis | Phase 2 | Status: ACTIVE_NOT_RECRUITING